BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32664214)

  • 1. Inhibition of HDAC1/2 Along with TRAP1 Causes Synthetic Lethality in Glioblastoma Model Systems.
    Nguyen TTT; Zhang Y; Shang E; Shu C; Quinzii CM; Westhoff MA; Karpel-Massler G; Siegelin MD
    Cells; 2020 Jul; 9(7):. PubMed ID: 32664214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of Synthetic Lethality by Activation of Mitochondrial ClpP and Inhibition of HDAC1/2 in Glioblastoma.
    Nguyen TTT; Shang E; Schiffgens S; Torrini C; Shu C; Akman HO; Prabhu VV; Allen JE; Westhoff MA; Karpel-Massler G; Siegelin MD
    Clin Cancer Res; 2022 May; 28(9):1881-1895. PubMed ID: 35417530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitochondrial matrix chaperone and c-myc inhibition causes enhanced lethality in glioblastoma.
    Ishida CT; Shu C; Halatsch ME; Westhoff MA; Altieri DC; Karpel-Massler G; Siegelin MD
    Oncotarget; 2017 Jun; 8(23):37140-37153. PubMed ID: 28415755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses.
    Karpel-Massler G; Ishida CT; Bianchetti E; Shu C; Perez-Lorenzo R; Horst B; Banu M; Roth KA; Bruce JN; Canoll P; Altieri DC; Siegelin MD
    Cancer Res; 2017 Jul; 77(13):3513-3526. PubMed ID: 28522750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined HDAC and Bromodomain Protein Inhibition Reprograms Tumor Cell Metabolism and Elicits Synthetic Lethality in Glioblastoma.
    Zhang Y; Ishida CT; Ishida W; Lo SL; Zhao J; Shu C; Bianchetti E; Kleiner G; Sanchez-Quintero MJ; Quinzii CM; Westhoff MA; Karpel-Massler G; Canoll P; Siegelin MD
    Clin Cancer Res; 2018 Aug; 24(16):3941-3954. PubMed ID: 29764852
    [No Abstract]   [Full Text] [Related]  

  • 6. BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma.
    Ishida CT; Bianchetti E; Shu C; Halatsch ME; Westhoff MA; Karpel-Massler G; Siegelin MD
    Oncotarget; 2017 May; 8(18):29558-29573. PubMed ID: 28418907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma.
    Zhang Y; Ishida CT; Shu C; Kleiner G; Sanchez-Quintero MJ; Bianchetti E; Quinzii CM; Westhoff MA; Karpel-Massler G; Siegelin MD
    Sci Rep; 2018 May; 8(1):7373. PubMed ID: 29743557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models.
    Nguyen TTT; Zhang Y; Shang E; Shu C; Torrini C; Zhao J; Bianchetti E; Mela A; Humala N; Mahajan A; Harmanci AO; Lei Z; Maienschein-Cline M; Quinzii CM; Westhoff MA; Karpel-Massler G; Bruce JN; Canoll P; Siegelin MD
    J Clin Invest; 2020 Jul; 130(7):3699-3716. PubMed ID: 32315286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.
    Karpel-Massler G; Bâ M; Shu C; Halatsch ME; Westhoff MA; Bruce JN; Canoll P; Siegelin MD
    Oncotarget; 2015 Nov; 6(34):36456-71. PubMed ID: 26474387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms.
    Pinkerneil M; Hoffmann MJ; Deenen R; Köhrer K; Arent T; Schulz WA; Niegisch G
    Mol Cancer Ther; 2016 Feb; 15(2):299-312. PubMed ID: 26772204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.
    Stubbs MC; Kim W; Bariteau M; Davis T; Vempati S; Minehart J; Witkin M; Qi J; Krivtsov AV; Bradner JE; Kung AL; Armstrong SA
    Clin Cancer Res; 2015 May; 21(10):2348-58. PubMed ID: 25688158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDAC inhibition activates the apoptosome via Apaf1 upregulation in hepatocellular carcinoma.
    Buurman R; Sandbothe M; Schlegelberger B; Skawran B
    Eur J Med Res; 2016 Jun; 21(1):26. PubMed ID: 27342975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems.
    Shang E; Zhang Y; Shu C; Ishida CT; Bianchetti E; Westhoff MA; Karpel-Massler G; Siegelin MD
    Sci Rep; 2018 Oct; 8(1):15383. PubMed ID: 30337641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Krüppel-like factor 9 and histone deacetylase inhibitors synergistically induce cell death in glioblastoma stem-like cells.
    Tung B; Ma D; Wang S; Oyinlade O; Laterra J; Ying M; Lv SQ; Wei S; Xia S
    BMC Cancer; 2018 Oct; 18(1):1025. PubMed ID: 30348136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibition prevents the growth of primary and metastatic osteosarcoma.
    McGuire JJ; Nerlakanti N; Lo CH; Tauro M; Utset-Ward TJ; Reed DR; Lynch CC
    Int J Cancer; 2020 Nov; 147(10):2811-2823. PubMed ID: 32599665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of taxol and Bcl-2 siRNA induces apoptosis in human glioblastoma cells and inhibits invasion, angiogenesis and tumour growth.
    George J; Banik NL; Ray SK
    J Cell Mol Med; 2009 Oct; 13(10):4205-18. PubMed ID: 19473291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of LXR Receptors and Inhibition of TRAP1 Causes Synthetic Lethality in Solid Tumors.
    Nguyen TTT; Ishida CT; Shang E; Shu C; Bianchetti E; Karpel-Massler G; Siegelin MD
    Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31181660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. X-radiation inhibits histone deacetylase 1 and 2, upregulates Axin expression and induces apoptosis in non-small cell lung cancer.
    Han Y; Zhang Y; Yang LH; Mi XY; Dai SD; Li QC; Xu HT; Yu JH; Li G; Zhao J; Han C; Yuan XM; Wang EH
    Radiat Oncol; 2012 Oct; 7():183. PubMed ID: 23110995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance.
    Santoro F; Botrugno OA; Dal Zuffo R; Pallavicini I; Matthews GM; Cluse L; Barozzi I; Senese S; Fornasari L; Moretti S; Altucci L; Pelicci PG; Chiocca S; Johnstone RW; Minucci S
    Blood; 2013 Apr; 121(17):3459-68. PubMed ID: 23440245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.
    Park KC; Heo JH; Jeon JY; Choi HJ; Jo AR; Kim SW; Kwon HJ; Hong SJ; Han KS
    BMC Cancer; 2015 Jan; 15():19. PubMed ID: 25613585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.